Contribution of the local RAS to hematopoietic function: a novel therapeutic target

The renin angiotensin system (RAS) has long been a known endocrine system that is involved in regulation of blood pressure and fluid balance. Over the last 2 decades, evidence has accrued that shows that there are local RAS that can affect cellular activity, tissue injury and tissue regeneration....

Full description

Bibliographic Details
Main Authors: Kathleen E. Rodgers, Gere S. diZerega
Format: Article
Language:English
Published: Frontiers Media S.A. 2013-10-01
Series:Frontiers in Endocrinology
Subjects:
Online Access:http://journal.frontiersin.org/Journal/10.3389/fendo.2013.00157/full
_version_ 1818981665966391296
author Kathleen E. Rodgers
Gere S. diZerega
Gere S. diZerega
author_facet Kathleen E. Rodgers
Gere S. diZerega
Gere S. diZerega
author_sort Kathleen E. Rodgers
collection DOAJ
description The renin angiotensin system (RAS) has long been a known endocrine system that is involved in regulation of blood pressure and fluid balance. Over the last 2 decades, evidence has accrued that shows that there are local RAS that can affect cellular activity, tissue injury and tissue regeneration. There are locally active ligand peptides, mediators, receptors and signaling pathways of the RAS in the bone marrow (BM). This system is fundamentally involved and controls the essential steps of primitive and definitive blood cell production. Hematopoiesis, erythropoiesis, myelopoiesis, thrombopoiesis, formation of monocytic and lymphocytic lineages, as well as stromal elements are regulated by the local BM RAS. The expression of a local BM RAS has been shown in very early, primitive embryonic hematopoiesis. Angiotensin-converting enzyme (ACE-1, CD143) is expressed on the surface of hemangioblasts and isolation of the CD143 positive cells allows for recovery of all hemangioblast activity, the first endothelial and hematopoietic cells, forming the marrow cavity in the embryo. CD143 expression also marks long-term blood-forming CD34+ BM cells. Expression of receptors of the RAS is modified in the BM with cellular maturation and by injury. Ligation of the receptors of the RAS has been shown to modify the status of the BM resulting in accelerated hematopoiesis after injury. The aim of the present review is to outline the known functions of the local BM RAS within the context of primitive and definitive hematopoiesis as well as modification of BM recovery by administration of exogenous ligands of the RAS. Targeting the actions of local RAS molecules could represent a valuable therapeutic option for the management of BM recovery after injury as well as neoplastic disorders.
first_indexed 2024-12-20T17:34:56Z
format Article
id doaj.art-85953e3f8c034b9dbaed3ef453c0f5bc
institution Directory Open Access Journal
issn 1664-2392
language English
last_indexed 2024-12-20T17:34:56Z
publishDate 2013-10-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Endocrinology
spelling doaj.art-85953e3f8c034b9dbaed3ef453c0f5bc2022-12-21T19:31:14ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922013-10-01410.3389/fendo.2013.0015765288Contribution of the local RAS to hematopoietic function: a novel therapeutic targetKathleen E. Rodgers0Gere S. diZerega1Gere S. diZerega2School of Pharmacy University of Southern CaliforniaUS Biotest, Inc.Keck School of Medicine at USCThe renin angiotensin system (RAS) has long been a known endocrine system that is involved in regulation of blood pressure and fluid balance. Over the last 2 decades, evidence has accrued that shows that there are local RAS that can affect cellular activity, tissue injury and tissue regeneration. There are locally active ligand peptides, mediators, receptors and signaling pathways of the RAS in the bone marrow (BM). This system is fundamentally involved and controls the essential steps of primitive and definitive blood cell production. Hematopoiesis, erythropoiesis, myelopoiesis, thrombopoiesis, formation of monocytic and lymphocytic lineages, as well as stromal elements are regulated by the local BM RAS. The expression of a local BM RAS has been shown in very early, primitive embryonic hematopoiesis. Angiotensin-converting enzyme (ACE-1, CD143) is expressed on the surface of hemangioblasts and isolation of the CD143 positive cells allows for recovery of all hemangioblast activity, the first endothelial and hematopoietic cells, forming the marrow cavity in the embryo. CD143 expression also marks long-term blood-forming CD34+ BM cells. Expression of receptors of the RAS is modified in the BM with cellular maturation and by injury. Ligation of the receptors of the RAS has been shown to modify the status of the BM resulting in accelerated hematopoiesis after injury. The aim of the present review is to outline the known functions of the local BM RAS within the context of primitive and definitive hematopoiesis as well as modification of BM recovery by administration of exogenous ligands of the RAS. Targeting the actions of local RAS molecules could represent a valuable therapeutic option for the management of BM recovery after injury as well as neoplastic disorders.http://journal.frontiersin.org/Journal/10.3389/fendo.2013.00157/fullBone MarrowHematopoiesisStem Cellsrenin angiotensin systemmyelosuppressionprimitive
spellingShingle Kathleen E. Rodgers
Gere S. diZerega
Gere S. diZerega
Contribution of the local RAS to hematopoietic function: a novel therapeutic target
Frontiers in Endocrinology
Bone Marrow
Hematopoiesis
Stem Cells
renin angiotensin system
myelosuppression
primitive
title Contribution of the local RAS to hematopoietic function: a novel therapeutic target
title_full Contribution of the local RAS to hematopoietic function: a novel therapeutic target
title_fullStr Contribution of the local RAS to hematopoietic function: a novel therapeutic target
title_full_unstemmed Contribution of the local RAS to hematopoietic function: a novel therapeutic target
title_short Contribution of the local RAS to hematopoietic function: a novel therapeutic target
title_sort contribution of the local ras to hematopoietic function a novel therapeutic target
topic Bone Marrow
Hematopoiesis
Stem Cells
renin angiotensin system
myelosuppression
primitive
url http://journal.frontiersin.org/Journal/10.3389/fendo.2013.00157/full
work_keys_str_mv AT kathleenerodgers contributionofthelocalrastohematopoieticfunctionanoveltherapeutictarget
AT geresdizerega contributionofthelocalrastohematopoieticfunctionanoveltherapeutictarget
AT geresdizerega contributionofthelocalrastohematopoieticfunctionanoveltherapeutictarget